847-86-9

Basic information

• Product Name: HYDROCODONE BITARTRATE RELATED COMPOUND A CII (70 MG) (MORPHINAN-6-ONE, 4-HYDROXY-3-METHOXY-17-METHYL)
• Synonyms: HYDROCODONE BITARTRATE RELATED COMPOUND A CII (70 MG) (MORPHINAN-6-ONE, 4-HYDROXY-3-METHOXY-17-METHYL);4-hydroxy-3-methoxy-17-methyl-morphinan-6-on;4-hydroxy-3-methoxy-n-methyl-6-oxo-morphina;4-hydroxy-3-methoxy-n-methyl-6-oxomorphinan;dihydrothebainone;ram-345;4-hydroxy-3-methoxy-17-methylmorphinan-6-one;3-Methoxy-4-hydroxy-6-oxo-17-methylmorphinan
• CAS NO: 847-86-9
• Molecular Formula: C₁₈H₂₃NO₃
• Molecular Weight: 301.38012
• EINECS: 212-696-5
• Product Categories: Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 847-86-9.mol
• Article Data: 16

Chemical Properties

• Melting Point: 150-151 °C(Solv: ethanol (64-17-5))
• Boiling Point: 470.3°C at 760 mmHg
• Flash Point: 238.2°C
• Appearance: /
• Density: 1.26g/cm³
• Vapor Pressure: 1.81E-09mmHg at 25°C
• Refractive Index: 1.619
• PKA: 8.55±0.20(Predicted)
• CAS DataBase Reference: HYDROCODONE BITARTRATE RELATED COMPOUND A CII (70 MG) (MORPHINAN-6-ONE, 4-HYDROXY-3-METHOXY-17-METHYL)(CAS DataBase Reference)
• NIST Chemistry Reference: HYDROCODONE BITARTRATE RELATED COMPOUND A CII (70 MG) (MORPHINAN-6-ONE, 4-HYDROXY-3-METHOXY-17-METHYL)(847-86-9)
• EPA Substance Registry System: HYDROCODONE BITARTRATE RELATED COMPOUND A CII (70 MG) (MORPHINAN-6-ONE, 4-HYDROXY-3-METHOXY-17-METHYL)(847-86-9)

Safety Data

• Hazardous Substances Data: 847-86-9(Hazardous Substances Data)

Usage

Chemical Properties

Pink Solid

Uses

Morphinan derivative. Used in the preparation of ABC drug transporter inhibitors.

InChI:InChI=1/C18H23NO3/c1-19-8-7-18-10-12(20)4-5-13(18)14(19)9-11-3-6-15(22-2)17(21)16(11)18/h3,6,13-14,21H,4-5,7-10H2,1-2H3/t13-,14-,18+/m0/s1

Upstream product

• 467-98-1 7,8-didehydro-4-hydroxy-3-methoxy-17-methyl-morphinan-6-one 
• 7647-01-0 hydrogenchloride 
• 75-08-1 ethanethiol 
• 64-17-5 ethanol 
• 99887-90-8 1-bromo-4-hydroxy-3-methoxy-17-methyl-morphin-7-en-6-one 
• 7732-18-5 water 
• 467-99-2 4-hydroxy-3-methoxy-17-methyl-morphin-8-en-6-one 
• 124152-42-7 1-bromo-4-hydroxy-3-methoxy-17-methyl-14α-morphin-7-en-6-one-(2,4-dinitro-phenylhydrazone) 
• 106954-42-1 1-bromo-4-hydroxy-3-methoxy-17-methyl-morphin-7-en-6-one-(2,4-dinitro-phenylhydrazone) 
• 76-57-3 codeine 
• 115-37-7 thebaine 
• 52-28-8 codeine phosphate 
• 62959-29-9 (-)-2-hydroxydihydrothebainone 
• 70962-36-6 (R)-1-(3,5-dihydroxy-4-methoxybenzyl)-1,2,3,4,5,8-hexahydro-6-methoxy-2-methylisoquinoline 

Downstream Products

• 51547-73-0 1-Brom-4,5α-epoxy-3-methoxy-17-methyl-morphinan-6-on 
• 62959-28-8 1-bromodihydrothebainone 
• 4978-42-1 dihydrothebainone-4-phenyl ether 
• 2246-20-0 3-methoxy-17-methylmorphinan-6-one 
• 74924-36-0 dihydrothebainone-4-phenyl ether ethylene glycol ketal 
• 3327-79-5 (-)-tetrahydrodeoxycodeine 

Relevant articles and documents

Deconstructive Asymmetric Total Synthesis of Morphine-Family Alkaloid (?)-Thebainone A

Herein, we describe the development of a deconstructive strategy for the first asymmetric synthesis of (?)-thebainone A, capitalizing on an enantioselective C?C bond activation and a C?O bond cleavage reaction. The rhodium-catalyzed asymmetric “cut-and-sew” transformation between sterically hindered trisubstituted alkenes and benzocyclobutenones allowed efficient construction of the fused A/B/C rings and the quaternary center of the natural product. The newly optimized conditions show broad substrate scope and excellent enantioselectivity (up to 99.5:0.5 er). Taking advantage of boron-mediated ether bond cleavage, we completed the synthesis of the morphine alkaloid (?)-thebainone A by two complementary routes.

-

-

Synthesis and pharmacological evaluation of aminothiazolomorphinans at the Mu and Kappa opioid receptors

Previous studies with aminothiazolomorphinans suggested that this class of opioid ligands may be useful as a potential pharmacotherapeutic to decrease drug abuse. Novel aminothiazole derivatives of cyclorphan were prepared to evaluate a series of aminothiazolomorphinans with varying pharmacological properties at the κ opioid receptor (KOR) and μ opioid receptor (MOR). This study was focused on exploring the regioisomeric analogs with the aminothiazole on the C-ring of the morphinan skeleton. Receptor binding and [35S] GTPγS binding assays were used to characterize the affinity and pharmacological properties of the aminothiazolomorphinans. Intracranial self-stimulation (ICSS) was used to compare the effects of a representative aminothiazolomorphinan with the morphinan mixed-KOR/MOR agonist butorphan (MCL-101) on brain-stimulation reward.

CONVERSION OF THEBAINE TO MORPHINE DERIVATIVES

The present invention provides methods for the conversion of thebaine to a morphine derivative, such as hydrocodone. Novel ketal intermediates of the conversion are provided. A one-pot procedure for the conversion comprises treating thebaine with an acid in the presence of a metal catalyst.